Indefinite Delivery Contract 75D30123D16687
Award Date
6/14/23
Last Date to Order
6/6/24
Federal Agency
CDC Pittsburgh
Awardee
Novavax Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Novavax Inc. to provide adult COVID-19 vaccines. The contract has a ceiling value of $13,961,250 and a period of performance through May 31, 2025. As a prime contractor, Novavax will deliver COVID-19 vaccine products and services out of its Maryland facility to support the CDC's public health response. Novavax is an experienced federal contractor, having previously received a $45.7...
The federal contract IDV award is for the provision of COVID-19 pediatric vaccines by Novavax Inc. (Novavax) to the Centers for Disease Control and Prevention (CDC). The $116 million IDV contract has an ultimate completion date of May 31, 2025 and is a multiple award IDV, meaning task orders will be competed among multiple awardees. Novavax has previously received federal contracts from the Department of the Army and has also served as a subcontractor on other government contracts. The purpose...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Novavax Inc., a biotechnology company that develops and produces recombinant protein nanoparticle vaccines. The $116 million contract is to provide pediatric COVID-19 vaccines if regulatory approval is obtained. The IDC is a multiple award vehicle, meaning there are multiple contractors that can compete for individual task orders. The period of performance runs through June 6, 2024....
This Federal Supply Schedule contract was awarded to Novavax Inc. by the Department of Veterans Affairs to provide pharmaceuticals, drugs, and hematology-related products. The contract has a ceiling value of $800,000 and a period of performance through September 2025. As a prime contractor, Novavax has provided COVID-19 vaccine research, development, and manufacturing services to support the Army's medical research programs under a separate $45.7 million contract. Novavax also holds Indefinite...
This Federal Supply Schedule (FSS) contract, awarded by the Department of Veterans Affairs (VA) to Novavax Inc., provides pharmaceuticals and hematology-related products under Schedule 65 I B. The contract has a ceiling value of $800,000 and a period of performance through July 2023. As the prime contractor, Novavax will deliver these products and services from its facilities to support the VA's medical programs. Novavax, a biotechnology company focused on recombinant protein nanoparticle...
The federal contract IDV award is for the delivery of pediatric COVID-19 vaccines to the Centers for Disease Control and Prevention (CDC). The prime contractor is Moderna US, Inc., a biotechnology company that develops and manufactures messenger RNA (mRNA) therapeutics and vaccines. The contract is a multiple-award indefinite delivery contract with a period of performance ending on May 31, 2026 and a ceiling value of $196,917,000.00. Under this contract, Moderna US, Inc. will provide continued...
The federal contract IDV award is for the procurement of COVID-19 mRNA vaccines from Moderna US, Inc., a subsidiary of Modernatx, Inc. The Centers for Disease Control and Prevention (CDC), a civilian agency, awarded this multiple award indefinite delivery contract with a ceiling value of $117,420,333 and a period of performance through September 30, 2025. The contract builds upon previous COVID-19 vaccine procurements by the Biomedical Advanced Research and Development Authority and the...
The federal contract IDV awarded to Glaxosmithkline, LLC is a $83,834,950 Indefinite Delivery Contract to provide a range of adult vaccines to the Centers for Disease Control and Prevention (CDC) for a period of performance through June 30, 2019. The single-award contract was issued without any set-aside designation. The contract aims to procure various pharmaceutical products and immunization services to support public health initiatives, including influenza vaccines, hepatitis vaccines,...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Moderna US, Inc. as the prime contractor. The contract has a ceiling value of $1,631,450.00 and a period of performance ending on June 30, 2026. The purpose of this contract is to procure adult vaccines, specifically COVID-19 mRNA vaccines, in support of the government's preparedness and response efforts. Moderna US, Inc. is a biotechnology company that develops and manufactures mRNA...
The federal contract IDV award is a $1,097,801,491.00 Indefinite Delivery Contract issued by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc., a large pharmaceutical manufacturer, for the procurement of COVID-19 pediatric vaccines. The contract has a period of performance from June 1, 2024 to September 30, 2025 and does not utilize any small business set-asides. This IDV contract serves as a vehicle for the CDC to issue task orders and delivery orders to Pfizer for the...